The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Hidetoshi Sumimoto, Fumie Imabayashi, Tomoko Iwata, Yutaka Kawakami

Research output: Contribution to journalArticle

386 Citations (Scopus)

Abstract

The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAFV600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF V600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor α by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAFV600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAFV600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system. JEM

Original languageEnglish
Pages (from-to)1651-1656
Number of pages6
JournalJournal of Experimental Medicine
Volume203
Issue number7
DOIs
Publication statusPublished - 2006 Jul 10

Fingerprint

Immune Evasion
RNA Interference
Mitogen-Activated Protein Kinases
Melanoma
Mitogen-Activated Protein Kinase Kinases
Neoplasms
STAT3 Transcription Factor
Interleukin-12
Immunosuppressive Agents
Interleukin-10
Dendritic Cells
Vascular Endothelial Growth Factor A
Lipopolysaccharides
Immune System
Interleukin-6
Down-Regulation
Tumor Necrosis Factor-alpha
Cell Proliferation
Cytokines
Phenotype

ASJC Scopus subject areas

  • Immunology

Cite this

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. / Sumimoto, Hidetoshi; Imabayashi, Fumie; Iwata, Tomoko; Kawakami, Yutaka.

In: Journal of Experimental Medicine, Vol. 203, No. 7, 10.07.2006, p. 1651-1656.

Research output: Contribution to journalArticle

Sumimoto, Hidetoshi ; Imabayashi, Fumie ; Iwata, Tomoko ; Kawakami, Yutaka. / The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. In: Journal of Experimental Medicine. 2006 ; Vol. 203, No. 7. pp. 1651-1656.
@article{33392699c967438ebd41fecc99317617,
title = "The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells",
abstract = "The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAFV600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF V600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor α by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAFV600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAFV600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system. JEM",
author = "Hidetoshi Sumimoto and Fumie Imabayashi and Tomoko Iwata and Yutaka Kawakami",
year = "2006",
month = "7",
day = "10",
doi = "10.1084/jem.20051848",
language = "English",
volume = "203",
pages = "1651--1656",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "7",

}

TY - JOUR

T1 - The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

AU - Sumimoto, Hidetoshi

AU - Imabayashi, Fumie

AU - Iwata, Tomoko

AU - Kawakami, Yutaka

PY - 2006/7/10

Y1 - 2006/7/10

N2 - The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAFV600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF V600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor α by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAFV600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAFV600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system. JEM

AB - The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAFV600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF V600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor α by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAFV600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAFV600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system. JEM

UR - http://www.scopus.com/inward/record.url?scp=33745859743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745859743&partnerID=8YFLogxK

U2 - 10.1084/jem.20051848

DO - 10.1084/jem.20051848

M3 - Article

C2 - 16801397

AN - SCOPUS:33745859743

VL - 203

SP - 1651

EP - 1656

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 7

ER -